Get startedLog in
    Picture of NovoCure logo

    NVCR — NovoCure News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapHigh Flyer
    All News

    Brief: Novocure Provides Update On Phase 3 Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy In Platinum-Resistant Ovarian Cancer

    Picture of NovoCure logoNovoCure
    28/08/2023 12:09
    Aug 28 (Reuters) - Novocure Ltd  NVCR.O :
    * NOVOCURE PROVIDES UPDATE ON PHASE 3 ENGOT-OV50 / GOG-3029
/
INNOVATE-3 TRIAL EVALUATING TUMOR TREATING FIELDS THERAPY IN
PLATINUM-RESISTANT OVARIAN CANCER
    * NOVOCURE LTD - TRIAL DID NOT MEET ITS PRIMARY ENDPOINT OF
OVERALL SURVIVAL (OS) AT FINAL ANALYSIS
    * NOVOCURE LTD - TTFIELDS THERAPY WAS WELL-TOLERATED WITH NO
ADDED
SYSTEMIC TOXICITIES

Source text for Eikon:  ID:nBw2WdKd5a 
Further company coverage:  NVCR.O

    Recent news on NovoCure

    See all news